Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide.

导出 OA

翻译打印收藏纠错

第一作者： Wassim,Abida

第一单位： Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York.

作者： Wassim,Abida ^[1] ; Andrew W,Hahn ^[2] ; Neal,Shore ^[3] ; Neeraj,Agarwal ^[4] ; Paul,Sieber ^[5] ; Matthew R,Smith ^[6] ; Tanya,Dorff ^[7] ; Paul,Monk ^[8] ; Matthew,Rettig ^[9] ; Rupal,Patel ^[10] ; Anne,Page ^[10] ; Maureen,Duff ^[10] ; Rongda,Xu ^[10] ; Jian,Wang ^[10] ; Shravani,Barkund ^[10] ; Aleksandr,Pankov ^[10] ; Amber,Wang ^[10] ; Melissa R,Junttila ^[10] ; Pratik S,Multani ^[10] ; Anneleen,Daemen ^[10] ; Edna,Chow Maneval ^[10] ; Christopher J,Logothetis ^[2] ; Michael J,Morris ^[1]

作者单位： Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York. ^[1] Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. ^[2] CURC, Myrtle Beach, South Carolina. ^[3] Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah. ^[4] Keystone Urology Specialists, Lancaster, Pennsylvania. ^[5] Massachusetts General Hospital, Boston, Massachusetts. ^[6] City of Hope, Duarte, California. ^[7] The Ohio State University, Arthur James Cancer Hospital, Columbus, Ohio. ^[8] VA Greater Los Angeles, Los Angeles, California. ^[9] ORIC Pharmaceuticals, South San Francisco, California. ^[10]